alexion continu exceed expect solid
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
methodolog valu compani
slightli expect solid progress toward
convert soliri patient next-gener ultomiri
continu pipelin expans cost remain within
reason level total third-quart revenu
billion last year adjust oper
margin improv basi point despit
concern brand biosimilar competit think
narrow-moat alexion well posit hold patient
share four rare ultrarar complement-medi
diseas soliri treat addit seen
pipelin flourish thank acquisit collabor
deal provid addit avenu growth
rare diseas adjust manag rais
full-year guidanc maintain fair valu
estim per share
key question face alexion fare
soliri impend biosimilar threat think alexion
result everi quarter support thesi
next-gener ultomiri conveni
dose offer compel reason patient switch
also think mani patient reluct switch
back less-conveni dose biosimilar enter
market oct elig soliri
patient convert ultomiri mark impress
progress toward compani goal convers
progress germani japan addit ultomiri
recent garner approv second indic atyp
hemolyt urem syndrom ahu allow alexion
switch ahu patient well ahead competit
entri think alexion network patient doctor
support futur commerci effort ultomiri
continu garner approv new indic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria
neuromyel optica spectrum disord nmosd next-gener
ultomiri approv pnh ahu strensiq kanuma target
ultrarar metabol diseas alexion pipelin target rare diseas
high unmet need hematolog nephrolog metabol diseas neurolog
cardiolog area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
importantli even alexion focus ultomiri
convers complement franchis soliri
ultomiri continu see new growth thank soliri
continu penetr gener myasthenia gravi
gmg newli approv neuromyel optica spectrum
disord nmosd third-quart revenu soliri
ultomiri total billion last year
expect two drug earn billion revenu
alexion metabol portfolio perform slightli
expect quarter testament compani
educ effort improv awar diagnosi
ultrarar
hypophosphatasia post million sale
last year driven entir volum growth
kanuma ultrarar lysosom acid lipas defici lal-
contribut million third quarter
last year volum last year
increas full-year estim two drug
million line manag new guidanc
expect continu modest contribut set
therapi ultrarar indic
rare ultrarar
alexion pipelin significantli expand sinc last
year compani current clinic candid
cardiolog other includ preclin compani
develop program across sever asset
repres mark improv time last
year firm hand drug candid outsid
complement franchis like compani focu
rare diseas high unmet need new
therapi significantli impact patient live
command strong price power believ focu
could continu support alexion narrow moat
current assign alexion neg moat trend
believ compani face signific competit
headwind soliri patent expir potenti
entri brand biosimilar competitor howev
see path alexion off-set pipelin
success overal think alexion healthi group
candid sever lucr diseas area variou
stage clinic develop definit
develop call regardless compani
healthi financi posit finish quarter
billion cash equival billion debt
closest catalyst horizon top-lin readout
phase trial danicopan patient paroxysm
hemolysi expect end year anoth
near-term catalyst phase readout stealth
biotherapeut elamipretid primari mitochondri
myopathi pmm expect first quarter next year
remind alexion option co-develop
commerci molecul follow readout
result believ could blockbust
opportun mitochondri diseas
inform soliri biosimilar threat pleas
see aug note amgen challeng alexion soliri
patent sell-off unwarr ultomiri
inform soliri brand competit
pleas see oct note ucb buy ra pharmaceut
billion challeng alexion soliri myasthenia
inform alexion recent acquisit
achillion well option agreement stealth
biotherapeut pleas see oct note alexion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
achillion share under-valued
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
